loading page

Effect of Ruxolitinb in refractory pruritus in a patient with high-risk polycythemia vera A Case Report
  • Mohanned Karrar,
  • mohamed yassin
Mohanned Karrar
Hamad Medical Corporation

Corresponding Author:[email protected]

Author Profile
mohamed yassin
HMC NCCCR
Author Profile

Abstract

Polycythemia vera (PV) associated pruritus is recognized as the most excruciating aspect of the disease. However, knowledge of pathophysiology, frequency, and precise character of PV-associated pruritus is limited. Ruxolitinib presented an encouraging and promising outcome in managing PV-related pruritus, especially in patients with symptoms refractory to other treatment modalities.
22 Dec 2022Submitted to Clinical Case Reports
26 Dec 2022Submission Checks Completed
26 Dec 2022Assigned to Editor
02 Jan 2023Reviewer(s) Assigned
07 Jan 2023Review(s) Completed, Editorial Evaluation Pending
07 Jan 2023Editorial Decision: Revise Minor